# PAM2L Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pam2l-biotechnologies

- Industry: Materials
- Headquarters: Shenzhen, China
- Website: www.pam2l.com
- Total disclosed funding: $5M
- Latest round: Angel (May 7, 2022)
- Investors on record: 3

## About

Established in 2021 and based in Shenzhen, China, PAM2L Biotechnologies operates as a synthetic biomaterials developer that provides protein and polysaccharide based materials. In Decmeber 2021, the company established material synthetic biology industry achievement transformation center cooperated with Chinese Academy of Sciences. In January 2023, it raised over CNY 100 million in pre-series A funding co-led by new investors GRC, Woyong Fund and Yunqi Partners. The consultant team comes from MIT, UCSB, Cornell University, Ruijin Hospital and Changzheng Hospital.

The company adopts synthetic biology and machine learning (BT-IT) technologies. Its products include protein and polysaccharide based materials. And its products can apply in pharmaceuticals, cosmetics and food fields.

Revenue primarily comes from sales of biomaterial products, customized biopolymer solutions, and technology licensing. Additional streams include collaborative R&D projects and partnerships with healthcare and industrial companies.

## Funding rounds

- Angel, May 7, 2022 — Tiantu Capital, CoStone Capital
- Angel, Dec 16, 2021, $5M — 5Y Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Angel
- Tiantu Capital (https://capitalatlas.ai/funds/tiantu-capital) — Angel
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Angel